Thursday, May 1, 2014
The Scripps Research Institute
has borrowed a page from the VC playbook and formed a separate corporation
called Scripps Advance LLC
that will house assets and IP related to discrete early stage research
projects. The goal is to attract pharma investment in translational assets. Johnson & Johnson's
California Innovation Center is on board as Scripps Advance's first partner.
The first company launched by Scripps Advance is Padlock Therapeutics Inc.,
which is developing inhibitors of peptidyl
arginine deiminase (PADI;
Cain, C. SciBX 7(17);
Published online May 1, 2014
L. SciBX 5(3); doi:10.1038/scibx.2012.61
K.-J. BioCentury 22(3), A13-A14; Jan. 20, 2014
J.S. et al. J. Clin. Invest. 123, 2981-2993 (2013)
D.M. et al. ACS Chem. Biol. 9, 913-921 (2014)
COMPANIES AND INSTITUTIONS
Atlas Venture, Cambridge, Mass.
Crucell Vaccine Institute, Leiden, the Netherlands
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
National Institutes of Health, Bethesda, Md.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
OrbiMed Advisors LLC, New York, N.Y.
Padlock Therapeutics Inc., Cambridge, Mass.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Scripps Advance LLC, Jupiter, Fla.
Scripps Florida, Jupiter, Fla.
The Scripps Research Institute, La Jolla, Calif.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan